Neurogene Inc. (NGNE)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

26.40 on 9 Oct 2026

0 buys0 sales at will11 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$90.35M

Free cash flow

$78.36M

Return on equity

-34.1%

Return on capital

-30.8%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
7 Jul 2026	Cvijic Christine Mikail President and CFO	Sold on a plan	$151.76K	4.8%
6 Jul 2026	Cvijic Christine Mikail President and CFO	Sold on a plan	$21.61K	0.7%
2 Jul 2026	Cvijic Christine Mikail President and CFO	Sold on a plan	$141.42K	4.4%
1 Jul 2026	Cvijic Christine Mikail President and CFO	Sold on a plan	$25.17K	0.8%
6 May 2026	Cvijic Christine Mikail President and CFO	Sold on a plan	$300.04K	9.3%
26 Mar 2026	McMinn Rachel Chief Executive Officer	Sold on a plan	$74.00K	0.2%

33out of 100

Profitability 0

Financial strength 59

Growth n/a

Insiders 50

Strongest on financial strength (59), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$1.13M

11 sales

Planned sales

100%

under a 10b5-1 plan